We had demonstrated that RGD-TRAIL had a higher affinity with some cancer cells and showed enhanced therapeutic efficacy in suppressing tumor growth of the human colon carcinoma (COLO-205) tumor-bearing mice, compared to free TRAIL with the equivalent dose29. Here, TNFSF10 is linked to cancer.